RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.Updates include positive functional, safety, and biomarker data for RGX-202, REGENXBIO’s investigational gene therapy for Duchenne muscular dystrophy.The data update looked at five patients who were six to 12 years old when they received the gene therapy RGX-202.The functional data demonstrate consistent benefit among dose level 2 participants at 9 and 12 months following treatment with RGX-202.Also Read: Re ...